Kai Riecke

Early clinical drug development from first-in-human to proof-of-concept in acute kidney injury, diabetic retinopathy, WH, contrast agents. Translational medicine, integrated study designs. Searching ways to improve clinical trials in Acute Kidney Injury: https://clinicaltrials.gov/study/NCT07368712

First-in human, food-effect, bioequivalence, special populations, cardiac safety

Responsible for strategic planning of a clinical development program, ph I to III, in anemia of inflammation, diabetic nephropathy, multiple myeloma, CLL, glioblastoma and other solid tumors. Multinational phase II PoC Studies, planning, start-up, medical supervision and monitoring.

Responsible for strategic planning of a clinical development program, ph I to II, in anemia of inflammation and diabetic nephropathy and for its implementation. Planning of multinational phase II PoC Study, medical supervision and monitoring.

Osteoarthritis: Phase I / II - preparation of phase III. Review of oncology licensing opportunities clinicaltrials.gov/ct2/show/NCT01091116

Responsibilities at study and development project level; Phase I / II: First in Human, Bioavailability, Food effect, adult and peds. clinicaltrials.gov/ct2/show/NCT00655083

Nonclin lead in inhalation, anti-infectives, ophthalmological, PET projects.

Nonclin lead in oncology, ophthalmology projects. Regulatory toxicology, e.g. ICH M4S

Nonclin lead in oncology projects. Regulatory toxicology, e.g. ICH M4S

Tox lead and Nonclin lead in oncology projects. In vivo toxicology: general, sensitization, tumorigenicity.

Institute for Clinical Pharmacology und Toxicology Toxicology in vitro/in vivo of Drugs and Chemicals Flow cytometry, morphology, reproduction toxicology, immunotoxicology, sensitization.

Physician in respiratory diseases: Infectious and Immunological Pneumonia, COPD, Tb, Sarcoidosis, Oncology